The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like.
Isotope effect studies on elimination reactions. VI. The mechanism of the bimolecular elimination reaction of 2-arylethylammonium ions
作者:P. J. Smith、A. N. Bourns
DOI:10.1139/v70-017
日期:1970.1.1
mechanism of the elimination reaction of 2-arylethyltrimethylammonium ions with ethoxideion in ethanol has been examined using tracer and kineticisotopeeffect techniques. Absence of exchange with solvent of both 2-phenylethyltrimethylammonium-2,2-d2 bromide and 2-(p-trifluoromethylphenyl)-ethyltrimethylammonium-2,2-d2 bromide and the observation of nitrogen isotope effects of 1.3 and 0.9%, respectively
NEUE BENZOXAZINONDERIVATE ALS LANGWIRKSAME BETAMIMETIKA ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN
申请人:BOEHRINGER INGELHEIM INTERNATIONAL GMBH
公开号:EP1730126A1
公开(公告)日:2006-12-13
US8735406B2
申请人:——
公开号:US8735406B2
公开(公告)日:2014-05-27
[DE] NEUE BENZOXAZINONDERIVATE ALS LANGWIRKSAME BETAMIMETIKA ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN<br/>[EN] NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES<br/>[FR] NOUVEAUX DERIVES DE BENZOXAZINONE UTILISES COMME BETA-MIMETIQUES DANS LE TRAITEMENT DES AFFECTIONS DES VOIES RESPIRATOIRES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2005092870A1
公开(公告)日:2005-10-06
Die vorliegende Erfindung betrifft die Verbindungen der allgemeinen Formel (I), worin die Reste R, R1, R2, R3 und A die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel, insbesondere zur Behandlung von entzündlichen und obstruktiven Atemwegserkrankungen.